title: Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
abstract: OBJECTIVE
  Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer.
  
  
  METHODS
  
  
  
  OBJECTIVE
  raising the clinical complete response rate from 5 to 25%.
  
  
  OBJECTIVE
  toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients.
  
  
  RESULTS
  Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites.
  
  
  CONCLUSIONS
  Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.
authors.affiliation: Radiation Oncology Unit, Department of Experimental, Diagnostic & Specialty Medicine - DIMES, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy.
authors.forename: Alessio Giuseppe
authors.initials: AG
authors.lastname: Morganti
authors.affiliation: Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Cellini
authors.affiliation: General Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy.
authors.forename: Samantha
authors.initials: S
authors.lastname: Mignogna
authors.affiliation: Cancer Research Consortium of West Michigan (CRCWM), Michigan State University, MI, USA.
authors.forename: Gilbert D A
authors.initials: GD
authors.lastname: Padula
authors.affiliation: Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy.
authors.forename: Luciana
authors.initials: L
authors.lastname: Caravatta
authors.affiliation: Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Deodato
authors.affiliation: Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Picardi
authors.affiliation: Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Macchia
authors.affiliation: Medical Physics Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy.
authors.forename: Savino
authors.initials: S
authors.lastname: Cilla
authors.affiliation: Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy.
authors.forename: Milly
authors.initials: M
authors.lastname: Buwenge
authors.affiliation: Oncology Department, General Hospital, Isernia, Italy.
authors.forename: Liberato
authors.initials: L
authors.lastname: Di Lullo
authors.affiliation: Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Gambacorta
authors.affiliation: Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Balducci
authors.affiliation: Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: Gian Carlo
authors.initials: GC
authors.lastname: Mattiucci
authors.affiliation: Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: Rosa
authors.initials: R
authors.lastname: Autorino
authors.affiliation: Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Valentini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D059248:Chemoradiotherapy; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D016896:Treatment Outcome
chemical_list: D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: Phase II; bevacizumab; chemo-sensitization; low-dose radiotherapy; metastatic colorectal cancer; multidisciplinary integrated treatments